RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Sparky, OT - When the FDA shoots down a company's drug twice, the red flags understandably go up. With AP Pharma, it isn't as if it's a brand new class of drug that regulators are justifiably leery of, it's just an extended release version of a boring old generic drug.

It could be the data was legitimately insufficient in some way, but it might also be that a particular FDA regulator is biased against the company for some reason.

We know the FDA is a revolving door where regulators routinely go back and forth into the industry they previously regulated, so a competing company could just buy off the regulator with a job offer. This happens a lot in other industries, like big agro (Monsanto), and banking and financial services (JP Morgan, Goldman Sachs). They call it 'regulatory capture'.

I've seen the FDA blatantly stonewall some drug programs I followed, for the flimsiest of reasons, and it's one reason why I no longer invest in the sector.